Patents by Inventor Wubin QIAN

Wubin QIAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for identification of tumor models
    Patent number: 11739387
    Abstract: The disclosure provides methods and compositions, e.g., kits, for identifying or authenticating a sample, e.g., a tumor model, based on the genotype of the sample at a group of SNP loci.
    Type: Grant
    Filed: May 25, 2021
    Date of Patent: August 29, 2023
    Assignee: CROWN BIOSCIENCE (SUZHOU) INC.
    Inventors: Sheng Guo, Xiaobo Chen, Wubin Qian, Henry Li
  • METHODS AND COMPOSITIONS FOR IDENTIFICATION OF TUMOR MODELS
    Publication number: 20210277486
    Abstract: The disclosure provides methods and compositions, e.g., kits, for identifying or authenticating a sample, e.g., a tumor model, based on the genotype of the sample at a group of SNP loci.
    Type: Application
    Filed: May 25, 2021
    Publication date: September 9, 2021
    Inventors: Sheng GUO, Xiaobo CHEN, Wubin QIAN, Henry LI
  • METHODS FOR DETERMINING RESPONSIVENESS TO MEK/ERK INHIBITORS
    Publication number: 20200123622
    Abstract: A method for predicting the responsiveness of a cancer cell to an MEK inhibitor, comprising detecting the presence of at least one mutation in one or more genes selected from the group consisting of ADAM12, COL14A1, TNN, and TP53, in the cancer cell, by contacting a nucleic acid sample derived from the cancer cell with at least one oligonucleotide which allows specific detection of the mutation; wherein presence of mutation in ADAM12, COL14A1, TNN, TP53 and/or any combination thereof is indicative of decreased responsiveness of the cancer cell to the ERK inhibitor.
    Type: Application
    Filed: October 30, 2019
    Publication date: April 23, 2020
    Inventors: Sheng GUO, Wubin QIAN, Jinying NING, Jing ZHANG, Jixian LI, Zhu MEI
  • Methods for determining responsiveness to MEK/ERK inhibitors
    Patent number: 10501805
    Abstract: A method for predicting the responsiveness of a cancer cell to an MEK inhibitor, comprising detecting the presence of at least one mutation in one or more genes selected from the group consisting of ADAM12, COL14A1, TNN, and TP53, in the cancer cell, by contacting a nucleic acid sample derived from the cancer cell with at least one oligonucleotide which allows specific detection of the mutation; wherein presence of mutation in ADAM12, COL14A1, TNN, TP53 and/or any combination thereof is indicative of decreased responsiveness of the cancer cell to the ERK inhibitor.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: December 10, 2019
    Assignee: CROWN BIOSCIENCE, INC. (TAICANG)
    Inventors: Sheng Guo, Wubin Qian, Jinying Ning, Jing Zhang, Jixian Li, Zhu Mei
  • METHODS FOR DETERMINING RESPONSIVENESS TO MEK/ERK INHIBITORS
    Publication number: 20170114414
    Abstract: A method for predicting the responsiveness of a cancer cell to an MEK inhibitor, comprising detecting the presence of at least one mutation in one or more genes selected from the group consisting of ADAM12, COL14A1, TNN, and TP53, in the cancer cell, by contacting a nucleic acid sample derived from the cancer cell with at least one oligonucleotide which allows specific detection of the mutation; wherein presence of mutation in ADAM12, COL14A1, TNN, TP53 and/or any combination thereof is indicative of decreased responsiveness of the cancer cell to the ERK inhibitor.
    Type: Application
    Filed: April 3, 2015
    Publication date: April 27, 2017
    Applicant: Crown Bioscience, Inc. (Taicang)
    Inventors: Sheng GUO, Wubin QIAN, Jinying NING, Jing ZHANG, Jixian LI, Zhu MEI